Citi analysts adjusted their outlook on CRISPR Therapeutics (NASDAQ:CRSP) stock, reducing the price target to $82 from $89 while maintaining a Buy rating. The stock, which has shown significant ...

Wide-moat GE HealthCare, or GEHC, is a top three global leader in the medical imaging market. It has a firmly established footprint in hospitals and health networks around the world, and it is ...

Baird analysts increased the price target on Crane NXT (NYSE: CXT) shares to $85.00, up from the previous $76.00, while ...

In addition, marketing and content production are becoming increasingly important components of the virtual retail ...

Across the recent three months, 16 analysts have shared their insights on Coinbase Glb COIN -4.18% Get Free Report , expressing a variety of opinions spanning from bullish to bearish.

Grok 3, xAI’s chatbot and ChatGPT challenger is in its final stages of development, reported Elon Musk on Thursday. The ...

Citi analyst Christopher Allen raised the firm’s price target on Robinhood (HOOD) to $60 from $45 and keeps a Neutral rating on the shares. The ...

Apple is reportedly preparing to launch its next iPhone SE, but one analyst warns against being too optimistic about the ...

Replimune's innovative cancer therapies, strong cash reserves, and FDA support position it to disrupt oncology markets. Click ...

The integration of AI technologies in financial services has revolutionized the industry, enabling institutions to leverage data for more accurate risk assessments, personalized customer interactions, ...

With little in the way of economic data in Europe to stir markets, investors are looking stateside for their cues. Economists expect the consumer price index data due at 1330 GMT to show that U.S.

Analysts at Keefe, Bruyette & Woods decreased their Q3 2025 earnings per share (EPS) estimates for shares of Meritage Homes in a research report issued on Wednesday, February 5th. Keefe, Bruyette & ...